Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) Radioprotective effect of montelukast sodium in rat lacrimal glands after radioi...
Journal Information
Vol. 32. Issue 5.
Pages 294-300 (September - October 2013)
Share
Share
Download PDF
More article options
Visits
758
Vol. 32. Issue 5.
Pages 294-300 (September - October 2013)
Original article
Radioprotective effect of montelukast sodium in rat lacrimal glands after radioiodine treatment
Visits
758
G. Kocaa, Z. Yalniz-Akkayab, S.S. Gültekinc,
Corresponding author
gultekinsinan@gmail.com

Corresponding author.
, N. Yumusakd, K. Demirela, M. Korkmaza, H.I. Atilgana, U.E. Altiparmakb, B. Onale, F. Ornekb
a Department of Nuclear Medicine, Ankara Training and Research Hospital, Ministry of Health, Ankara, Turkey
b Department of Ophthalmology, Ankara Training and Research Hospital, Ministry of Health, Ankara, Turkey
c Division of Nuclear Medicine, Diskapi Yildirim Beyazit Training and Research Hospital, Ministry of Health, Ankara, Turkey
d Department of Pathology, Harran University Faculty of Veterinary Medicine, Sanliurfa, Turkey
e Department of Pathology, Diskapi Yildirim Beyazit Training and Research Hospital, Ministry of Health, Ankara, Turkey
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (4)
Table 1. Distribution of histological inflammatory parameters in control, montelukast protected and non-protected animal groups according to the rat lacrimal gland types and their statistical significance levels.
Table 2. Distribution of morphological parameters in control, montelukast protected and non-protected groups according to the rat lacrimal gland types and their statistical significance levels.
Table 3. Distribution of cellular parameters in control, montelukast protected and non-protected groups according to the rat lacrimal gland types and their statistical significance levels.
Table 4. Distribution of histological findings according to the nucleus characteristics of rat lacrimal glands in the control group, radioiodine group and montelukast group.
Show moreShow less
Abstract
Purpose

The aim of this study was to evaluate the morphological changes of rat lacrimal glands at the third month following radioiodine (RAI) treatment and the radioprotective effect of montelukast (ML) sodium against RAI-related lacrimal gland damage.

Methods

Fifty female Wistar Albino rats were divided into three groups. The control group (n=10) consisted of rats with no intervention. RAI group (n=20) consisted of rats treated with oral 131I (111 MBq). The ML group (n=20) consisted of rats treated with intraperitoneal 10mg/kg/day ML sodium, starting three days before and continuing for one week after oral RAI administration. Intraorbital (IG), extraorbital (EG) and Harderian glands (HG) were removed bilaterally after three months.

Results

The existence of acinar atrophy, acinar fibrosis, abnormal cell lines, peripheral basophilia, cell size variation and decrease in amount of cytoplasm was significantly more common in the RAI-rat treated group than in the ML group, in each of the glands. The ML-treated group had less-frequent cell shape variation in EG (P=0.001) and HG (P=0.027), cell size variation in IG (P<0.001) and HG (P=0.01), ductal pathology in EG (P<0.001) and HG (P<0.001) and lipofuscin accumulation in EG (P=0.001) and in HG (P=0.01) than the RAI-treated group.

Conclusions

RAI treatment seems to cause morphological damage to rat lacrimal glands, and ML sodium effectively protects against damage to lacrimal glands.

Keywords:
Lacrimal gland
Montelukast sodium
Radioiodine-131
Rat
Radioprotection
Radioprotective agent
Resumen
Objetivo

El objetivo de este estudio fue evaluar los cambios morfológicos de las glándulas lagrimales de las ratas en el tercer mes después del tratamiento con iodo radiactivo (RAI) y el efecto radioprotector de montelukast (ML) sódico contra los daños causados por el RAI en la glándula lagrimal.

Métodos

Cincuenta ratas hembra albinas de raza Wistar fueron divididas en 3 grupos. El grupo de control (n=10) estaba formado por ratas no intervenidas. El grupo de RAI (n=20) estaba formado por ratas tratadas con 131I orales (111MBq). El grupo ML estaba formado por ratas tratadas con 10mg/kg/d de ML sódico intraperitoneal comenzando 3d antes y continuando durante una semana después de la administración oral del RAI. Las glándulas intraorbitarias (IG), las extraorbitarias (EG) y las de Harder (HG) se eliminaron bilateralmente en 3 meses.

Resultados

La existencia de atrofia acinar, fibrosis acinar, líneas celulares anormales, basofilia periférica, la variación de tamaño de las células y la disminución de la cantidad de citoplasma eran significativamente más común en todas las glándulas separadas en el grupo de ratas tratadas con RAI que en el grupo de ratas tratadas con ML. El grupo tratado con ML presentaba menor variación frecuente de la forma celular en las EG (p=0,001) y las HG (p=0,027), variación de tamaño de las células en las IG (p<0,001) y las HG (p=0,01), enfermedad ductal en las EG (p<0,001) y las HG (p<0,001) y menor acumulación de lipofuscina en las EG (p=0,001) y en las HG (p=0,01) que el grupo tratado con RAI.

Conclusiones

El tratamiento con RAI parece causar daño morfológico en las glándulas lagrimales de las ratas y el ML sódico protege eficazmente a las glándulas lagrimales de ese daño.

Palabras clave:
Glándula lagrimal
Montelukast sódico
Yodo radiactivo
Rata
Radioprotección
Agente radioprotector

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos